SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3559 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2082What is (if any) $37K/y price telling you about coming marketing "struggle&Miljenko Zuanic-3/28/2017
2081Dupixent CC slides: investor.regeneron.comDewDiligence_on_SI-3/28/2017
2080Dupi approved: finance.yahoo.comMiljenko Zuanic-3/28/2017
2079Here is how UBS value REGN, note NO single penny for RGC: "Valuation: $435Miljenko Zuanic-3/24/2017
2078REGN (Regeneration is leading developer, not Sanofi) is advancing anti-PD-1 intoMiljenko Zuanic-3/24/2017
2077No guesses from me, I do not know.Biotech Jim-3/23/2017
2076Any guesses on what they will price it at? I think I read somewhere analysts prFelix B-3/23/2017
2075How much value do you ascribe to RGC? I.e. what would it be worth as a standalonMiljenko Zuanic-3/22/2017
2074After UK early marketing approval, Le Trait facility failure were less likely, bMiljenko Zuanic-3/22/2017
2073March 29 PDUFA is crucial. About time the went after AMGN, and they better playBiotech Jim-3/22/2017
2072reuters.com This was predictable due to old IMNX soluble IL4R antagonist and laMiljenko Zuanic-3/21/2017
2071Interesting company for REGN to look at: alk.netMiljenko Zuanic-3/18/2017
2070For (as) trading opportunity, one can sell Mar-31 REGN puts (@370/372.5) for $10Miljenko Zuanic-3/17/2017
2069MDCO (LDL-C hypothesis) may not be right (best) approach. One should consider LpMiljenko Zuanic-3/17/2017
2068If anybody still likes the PCSK9 approach, today could be a very nice entry for Biotech Jim-3/17/2017
2067My prediction for Repatha CVOT was right on mark: twitter.com No CV death beneMiljenko Zuanic-3/17/2017
2066Yes, BOTOX manufacturing and formulation is art on its own,...Miljenko Zuanic-3/15/2017
2065I was bit sarcastic...Yes, it would be a lot of work to make an Eylea FoB. But iDewDiligence_on_SI-3/14/2017
2064I was bit sarcastic, aflibercept is bi-trap, so comp need to bio-engineer CHOP cMiljenko Zuanic-3/14/2017
2063AGN isn't planning to embark on new FoB programs, as far as I know. They'DewDiligence_on_SI-3/14/2017
2062Well, Saunders can promote AGN as much as he can , but REGN has head-up with IntMiljenko Zuanic-3/14/2017
2061AGN's Brent Saunders (on today's Barclays webcast) says Eylea will end uDewDiligence_on_SI-3/14/2017
2060UK gives early green light to Sanofi eczema drug REUTERS 4:10 AM ET 3/14/2017 Biotech Jim-3/14/2017
2059REGN2222 enrollment completed, results in 6 months. Fingers crossed. clinicaltrMiljenko Zuanic-3/13/2017
2058At least somewhere (with Intellia) they have progress. bizjournals.comMiljenko Zuanic-3/9/2017
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News